Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The effects of dulaglutide and a calorie-restricted diet (CRD) on visceral adipose tissue (VAT) and metabolic profiles in polycystic ovary syndrome (PCOS) have not been extensively investigated. In this study, we investigated whether dulaglutide combined with CRD could further reduce VAT and promote clinical benefits as compared with a CRD regimen alone in overweight or obese PCOS-affected women. Between May 2021 and May 2022, this single-center, randomized, controlled, open-label clinical trial was conducted. Overall, 243 participants with PCOS were screened, of which 68 overweight or obese individuals were randomly randomized to undergo dulaglutide combined with CRD treatment (n = 35) or CRD treatment alone (n = 33). The duration of intervention was set as the time taken to achieve a 7% weight loss goal from baseline body weight, which was restricted to 6 months. The primary endpoint was the difference in the change in VAT area reduction between the groups. The secondary endpoints contained changes in menstrual frequency, metabolic profiles, hormonal parameters, liver fat, and body composition. As compared with the CRD group, the dulaglutide + CRD group had a considerably shorter median time to achieve 7% weight loss. There was no significant between-group difference in area change of VAT reduction (−0.97 cm2, 95% confidence interval from −14.36 to 12.42, p = 0.884). As compared with CRD alone, dulaglutide + CRD had significant advantages in reducing glycated hemoglobin A1c and postprandial plasma glucose levels. The results of the analyses showed different changes in menstruation frequency, additional metabolic profiles, hormonal markers, liver fat, and body composition between the two groups did not differ significantly. Nausea, vomiting, constipation, and loss of appetite were the main adverse events of dulaglutide. These results emphasize the value of dietary intervention as the first line of treatment for PCOS-affected women, while glucagon-like peptide 1 receptor agonist therapy provides an efficient and typically well tolerated adjuvant therapy to aid in reaching weight targets based on dietary therapy in the population of overweight/obese PCOS-affected women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Subcutaneous and visceral adipose tissue: Structural and functional differences
Ibrahim, M. M. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00623.x · Cited by 2,238
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“Glucagon-like peptide 1 (GLP-1) is a peptide hormone released by gut enteroendocrine cells that improves glucose homeostasis and reduces body weight [12,13].”
BackgroundPolycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment
Escobar-Morreale, H. F. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.24 · Cited by 2,083
Stern, L., Iqbal, N., Seshadri, P., Chicano, K. L., Daily, D. A., McGrory, J., Williams, M., Gracely, E. J., & Samaha, F. F. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-10-200405180-00007 · Cited by 831
GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK
Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F., Serrano, M., Fernø, J., Salvador, J., Escalada, J., et al. (2014) · Diabetes · doi:10.2337/db14-0302 · Cited by 602 · cited 1×
“Glucagon-like peptide 1 (GLP-1) is a peptide hormone released by gut enteroendocrine cells that improves glucose homeostasis and reduces body weight [12,13].”
BackgroundCalorie restriction with or without time-restricted eating in weight loss
Liu, D., Huang, Y., Huang, C., Yang, S., Wei, X., Zhang, P., Guo, D., Lin, J., Xu, B., Li, C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2114833 · Cited by 516
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486 · cited 2×
“5 mg once-weekly dulaglutide as described in the Assessment of Weekly AdministRation of LY2189265 in Diabetes (AWARD) trials [46,47].”
MethodKraus, W. E., Bhapkar, M., Huffman, K. M., Pieper, C. F., Krupa Das, S., Redman, L. M., Villareal, D. T., Rochon, J., Roberts, S. B., Ravussin, E., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30151-2 · Cited by 407
Abdominal adiposity and the polycystic ovary syndrome
Escobar-Morreale, H. F., & Millán, J. L. S. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2007.07.003 · Cited by 386 · cited 1×
“The increased abdominal phenotype of fat distribution is a common manifestation in both normal-weight and overweight/obese women with PCOS, which forms vicious circles with hyperandrogenic states and insulin resistance (IR) [3,4].”
BackgroundMicklesfield, L. K., Goedecke, J. H., Punyanitya, M., Wilson, K. E., & Kelly, T. L. (2012) · Obesity · doi:10.1038/oby.2011.367 · Cited by 374 · cited 1×
“Lastly, although VAT was not measured using magnetic resonance imaging (MRI) or computed tomography (CT), DXA-VAT has been validated against either MRI or CT [51,52].”
MethodEffect of Calorie Restriction with or without Exercise on Body Composition and Fat Distribution
Redman, L. M., Heilbronn, L. K., Martin, C. K., Alfonso, A., Smith, S. R., Ravussin, E., & for the Pennington CALERIE Team (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2184 · Cited by 293
Kuchay, M. S., Krishan, S., Mishra, S. K., Choudhary, N. S., Singh, M. K., Wasir, J. S., Kaur, P., Gill, H. K., Bano, T., Farooqui, K. J., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05265-7 · Cited by 249 · cited 1×
“Previous trials that explored the effectiveness of dulaglutide in patients with type 2 diabetes (T2D) and non-alcoholic fatty liver disease showed discordant effects on liver transaminases and liver stiffness [42,43], and CRD was considered ineffective in improving aminotransferases and liver stiffness within a short-…”
BackgroundDumesic, D. A., Akopians, A. L., Madrigal, V. K., Ramirez, E., Margolis, D. J., Sarma, M. K., Thomas, A. M., Grogan, T. R., Haykal, R., Schooler, T. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2586 · Cited by 222 · cited 1×
“The increased abdominal phenotype of fat distribution is a common manifestation in both normal-weight and overweight/obese women with PCOS, which forms vicious circles with hyperandrogenic states and insulin resistance (IR) [3,4].”
BackgroundMcCrimmon, R. J., Catarig, A.-M., Frias, J. P., Lausvig, N. L., le Roux, C. W., Thielke, D., & Lingvay, I. (2020) · Diabetologia · doi:10.1007/s00125-019-05065-8 · Cited by 184 · cited 1×
“, Marlborough, Massachusetts, USA) were performed at baseline and after prespecified weight loss [23,24].”
BackgroundEffect of liraglutide on ectopic fat in polycystic ovary syndrome: Arandomized clinical trial
Frøssing, S., Nylander, M., Chabanova, E., Frystyk, J., Holst, J. J., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13053 · Cited by 178 · cited 1×
“In this trial, we found that dulaglutide combined with CRD provided additional benefits respecting HbA1c and PPG as compared with CRD after equivalent weight loss, which was consistent with earlier clinical trial findings showing that GLP-1 RAs could result in significant improvements in HbA1c and post-OGTT glucose le…”
ResultEffects of Weight Loss on Lean Mass, Strength, Bone, and Aerobic Capacity
WEISS, E. P., JORDAN, R. C., FRESE, E. M., ALBERT, S. G., & VILLAREAL, D. T. (2017) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001074 · Cited by 169 · cited 1×
“It is worth noting that the participants in both groups took a shorter period to achieve 7% weight loss than those in other studies [28,29], which might be explained by the high adherence and well implemented treatment protocol in the current study.”
ResultAhrén, B., Atkin, S. L., Charpentier, G., Warren, M. L., Wilding, J. P. H., Birch, S., Holst, A. G., & Leiter, L. A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13353 · Cited by 157
Santilli, F., Simeone, P. G., Guagnano, M. T., Leo, M., Maccarone, M. T., Di Castelnuovo, A., Sborgia, C., Bonadonna, R. C., Angelucci, E., Federico, V., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0589 · Cited by 114 · cited 1×
“It is worth noting that the participants in both groups took a shorter period to achieve 7% weight loss than those in other studies [28,29], which might be explained by the high adherence and well implemented treatment protocol in the current study.”
ResultJensterle, M., Kravos, N. A., Goričar, K., & Janez, A. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0155-9 · Cited by 93
Marzouk, T. M., & Sayed Ahmed, W. A. (2015) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2015.01.002 · Cited by 73
Visceral adiposity index as a predictor of clinical severity and therapeutic outcome of PCOS
Zheng, S.-H., & Li, X.-L. (2016) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1111327 · Cited by 63
Chang, K.-C., Shao, S.-C., Kuo, S., Yang, C.-Y., Chen, H.-Y., Chan, Y.-Y., & Ou, H.-T. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01148-8 · Cited by 28
Johnson, L. K., Holven, K. B., Nordstrand, N., Mellembakken, J. R., Tanbo, T., & Hjelmesæth, J. (2015) · Endocrine Connections · doi:10.1530/ec-15-0047 · Cited by 24 · cited 1×
“Levels of LH, FSH, PRL, FT, DHEAS, and SHBG did not alter significantly in either group after moderate reductions in body weight, which was consistent with previous studies’ findings [11,45].”
Result
Research works printed but not linked: 27
- Petraglia, 2003, Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome, Endocr. Rev., 24, 633, 10.1210/er.2002-0015 · DOI · Paper page
- Hoeger, 2006, Role of lifestyle modification in the management of polycystic ovary syndrome, Best Pract. Res. Clin. Endocrinol. Metab., 20, 293, 10.1016/j.beem.2006.03.008 · DOI
- Lim, S., Smith, C.A., Costello, M.F., MacMillan, F., Moran, L., and Ee, C. (2019). Barriers and facilitators to weight management in overweight and obese women living in Australia with PCOS: A qualitative study. BMC Endocr. Disord., 19. · DOI · Paper page
- Yoshimura, 2014, Lifestyle Intervention Involving Calorie Restriction with or without Aerobic Exercise Training Improves Liver Fat in Adults with Visceral Adiposity, J. Obes., 2014, 197216, 10.1155/2014/197216 · DOI · Paper page
- Huffman, K.M., Redman, L.M., Landerman, L.R., Pieper, C.F., Stevens, R.D., Muehlbauer, M.J., Wenner, B.R., Bain, J.R., Kraus, V.B., and Newgard, C.B. (2012). Caloric Restriction Alters the Metabolic Response to a Mixed-Meal: Results from a Randomized, Controlled Trial. PLoS ONE, 7. · DOI · Paper page
- Dawson, 2019, The Effect of Exenatide on Cardiovascular Risk Markers in Women with Polycystic Ovary Syndrome, Front. Endocrinol., 10, 189, 10.3389/fendo.2019.00189 · DOI · Paper page
- Liu, 2017, Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome, Clin. Endocrinol., 87, 767, 10.1111/cen.13454 · DOI · Paper page
- Amblee, 2016, Mode of administration of dulaglutide: Implications for treatment adherence, Patient Prefer. Adherence, 10, 975, 10.2147/PPA.S82866 · DOI · Paper page
- Eleni, 2004, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS), Hum. Reprod., 19, 41, 10.1093/humrep/deh098 · DOI · Paper page
- Huang, 2005, One-Year Intense Nutritional Counseling Results in Histological Improvement in Patients with Nonalcoholic Steatohepatitis: A Pilot Study, Am. J. Gastroenterol., 100, 1072, 10.1111/j.1572-0241.2005.41334.x · DOI · Paper page
- Eckel, 2014, 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 129, S76, 10.1161/01.cir.0000437740.48606.d1 · DOI · Paper page
- Dhaliwal, 2019, Changes in Visceral and Subcutaneous Fat in Youth with Type 2 Diabetes in the Today Study, Diabetes Care, 42, 1549, 10.2337/dc18-1935 · DOI
- Bredella, 2013, Assessment of Abdominal Fat Compartments Using DXA in Premenopausal Women from Anorexia Nervosa to Morbid Obesity: DXA for Assessment of Abdominal Fat, Obesity, 21, 2458, 10.1002/oby.20424 · DOI
- Panizza, C.E., Lim, U., Yonemori, K.M., Cassel, K.D., Wilkens, L.R., Harvie, M.N., Maskarinec, G., Delp, E.J., Lampe, J.W., and Shepherd, J.A. (2019). Effects of Intermittent Energy Restriction Combined with a Mediterranean Diet on Reducing Visceral Adiposity: A Randomized Active Comparator Pilot Study. Nutrients, 11. · DOI · Paper page
- Nylander, 2017, Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: A randomized clinical trial, Reprod. Biomed. Online, 35, 121, 10.1016/j.rbmo.2017.03.023 · DOI · Paper page
- Suliburska, 2016, The effects of a low-calorie diet or an isocaloric diet combined with metformin on sex hormones in obese women of child-bearing age, Acta Sci. Pol. Technol. Aliment., 15, 213, 10.17306/J.AFS.2016.2.21 · DOI
- Sookthai, 2018, Effects of intermittent and continuous calorie restriction on body weight and metabolism over 50 wk: A randomized controlled trial, Am. J. Clin. Nutr., 108, 933, 10.1093/ajcn/nqy196 · DOI · Paper page
- Tapsell, 2010, Short term effects of energy restriction and dietary fat sub-type on weight loss and disease risk factors, Nutr. Metab. Cardiovasc. Dis., 20, 317, 10.1016/j.numecd.2009.04.007 · DOI · Paper page
- Ferdinand, 2014, Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients with Type 2 Diabetes Mellitus, Hypertension, 64, 731, 10.1161/HYPERTENSIONAHA.114.03062 · DOI · Paper page
- Bagheri, 2018, Lipid profile change after bariatric surgeries: Laparoscopic gastric plication versus mini gastric bypass, Acta Chir. Belg., 119, 146, 10.1080/00015458.2018.1479022 · DOI
- Seko, 2017, Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus, Hepatol. Res., 47, 1206, 10.1111/hepr.12837 · DOI · Paper page
- Cunha, 2020, Efficacy of a 2-Month Very Low-Calorie Ketogenic Diet (VLCKD) Compared to a Standard Low-Calorie Diet in Reducing Visceral and Liver Fat Accumulation in Patients with Obesity, Front. Endocrinol., 11, 607, 10.3389/fendo.2020.00607 · DOI · Paper page
- Ahangari, 2018, The effect of vitamin D supplementation in combination with low-calorie diet on anthropometric indices and androgen hormones in women with polycystic ovary syndrome: A double-blind, randomized, placebo-controlled trial, J. Endocrinol. Investig., 41, 597, 10.1007/s40618-017-0785-9 · DOI
- Guo, 2020, Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials, Diabetes Ther., 11, 1821, 10.1007/s13300-020-00869-z · DOI
- Svendsen, 2018, Effect of intermittent versus continuous energy restriction on weight loss, maintenance and cardiometabolic risk: A randomized 1-year trial, Nutr. Metab. Cardiovasc. Dis., 28, 698, 10.1016/j.numecd.2018.03.009 · DOI · Paper page
- Keenan, S., Cooke, M.B., Chen, W.S., Wu, S., and Belski, R. (2022). The Effects of Intermittent Fasting and Continuous Energy Restriction with Exercise on Cardiometabolic Biomarkers, Dietary Compliance, and Perceived Hunger and Mood: Secondary Outcomes of a Randomised, Controlled Trial. Nutrients, 14. · DOI
- Nylander, 2018, Quantification of visceral adipose tissue in polycystic ovary syndrome: Dual-energy X-ray absorptiometry versus magnetic resonance imaging, Acta Radiol., 59, 13, 10.1177/0284185117711475 · DOI
Cited by
Polycystic Ovary Syndrome: Pathophysiology and Therapeutic Opportunities
Dong, J., & Rees, D. A. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2023-000548 · Cited by 123
The Role of Lifestyle Interventions in PCOS Management: A Systematic Review
Gautam, R., Maan, P., Jyoti, A., Kumar, A., Malhotra, N., & Arora, T. (2025) · Nutrients · doi:10.3390/nu17020310 · Cited by 115
Ismaiel, A., Scarlata, G. G. M., Boitos, I., Leucuta, D.-C., Popa, S.-L., Al Srouji, N., Abenavoli, L., & Dumitrascu, D. L. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01859-6 · Cited by 99
Jurczewska, J., Ostrowska, J., Chełchowska, M., Panczyk, M., Rudnicka, E., Kucharski, M., Smolarczyk, R., & Szostak-Węgierek, D. (2023) · Nutrients · doi:10.3390/nu15163652 · Cited by 37
Metadata
- Authors
- Zhang, Y., Qu, Z., Lu, T., Shao, X., Cai, M., Dilimulati, D., Gao, X., Mao, W., Hu, F., Su, L., Liao, Q., Han, T., Zhang, M., & Qu, S.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2023-01-20
- Volume
- 15
- Issue
- 3
- Pages
- 556
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W4317733039
- Cited by
- 45
- References
- 25
- FWCI
- 8.66
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- National Nature Science Foundation (81601269)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.